Since its first clinical application in 2002, transcatheter aortic valve replacement (TAVR) has grown from an exploratory technology to the cornerstone of the treatment of aortic valve disease. The release of 2024 Expert Consensus on Clinical Pathway for Transcatheter Aortic Valve Replacement in China marks a new phase of high-quality development for TAVR in China. This article will thoroughly interpret this programmatic document, comprehensively analyze its key links such as the basis of evidence-based medicine, preoperative clinical evaluation, perioperative imaging evaluation, standardized surgical process, perioperative comprehensive management and postoperative rehabilitation follow-up, explain its clinical path, provide comprehensive guidance for clinical practice, and help the majority of cardiovascular interventional physicians to move forward accurately in the new era of structural heart disease treatment.
